Array BioPharma Inc. (NASDAQ:ARRY) Assigned A Consensus Outperform Rating

Array BioPharma Inc. (NASDAQ:ARRY) stock is presently standing at about $11.44 and lots of equity research firms seem to have a target price set on the stock. The median one-year price target of 8 analysts covering the company is $13.00, which suggests the stock could still rise over 12 percent. The highest analyst price target is $15.00, which implies a rally of 69 percent. And a quick view of analyst notes show that 4 are rating the stock a buy while 3 rate ARRY a strong buy. There are 2 equity research firms advocating a Hold and 0 consider it Sell.

JP Morgan analysts provided their view on Array BioPharma Inc. (NASDAQ:ARRY) recently. The rating firm issued a Neutral rating to this company in a research note released on Feb 03, 2017. Leerink Partners analysts disclosed their opinion on Array BioPharma Inc. (NASDAQ:ARRY) recently. The rating firm gave a Mkt Perform rating to this stock in a research note published on Jan 30, 2017. According to a research note disclosed on Jul 23, 2010, analysts at UBS have upped their rating on these shares from Neutral to Buy.

Array BioPharma Inc. (NASDAQ:ARRY) Transactions Roundup

Several insiders were part of recent insider activity for the stock. Its 10% Owner Redmile Group, LLC sold 2,492,578 company shares for 15852800, in a transaction on 2016-09-28. Following the transaction, the 10% Owner is left with a stake of 16,658,072 shares, currently valued at $190568344. Meanwhile, 10% Owner Redmile Group, LLC sold 400,000 shares worth $1400000, through a transaction dated 2016-09-15. Following the completion of the transaction, the insider is left with a stake of 19,150,650 shares, amounting $219083436. ARRY 10% Owner Redmile Group, LLC also purchased 400,000 shares, at a stock price of $3.51. This transaction occurred on 2016-09-15 totals $1404000. After this transaction, the insider’s stake stands at 19,150,650 shares, with a market value of $219083436.

Executives hold 1.63 percent of the stock. Dr. Kevin Koch, PhD is one of the biggest insider owners in Array BioPharma Inc. (NASDAQ:ARRY), according to U.S. Securities and Exchange Commission (SEC) filings. The insider owns 786,917 shares which have current market value of around $9002330.48.Mr. Robert E. Conway is another major inside shareholder in the company. The insider owns 633,386 shares as of 0.37%, currently worth $7245935.84. Dr. Anthony D. Piscopio,PhD is ranked as third insider holder of the stock. This insider holds 553,527 shares with a market value around $6332348.88 as of recent close.

Array BioPharma Inc. (NASDAQ:ARRY) Earnings Outlook

In Array BioPharma Inc. (NASDAQ:ARRY)’s latest quarter, EPS moved to $-0.14 from $-0.20 in preceding quarter and revenues reached at $44.52M compared to $39.27M. Analysts had expected Array BioPharma Inc. (NASDAQ:ARRY) to post net income of about $-0.18 per share on $30.99M in revenue. Looking ahead, analysts on average predict that earnings for the current quarter would come in in the range of $-0.32 to $0.05. That is compared with the $-0.16 in EPS it reported during the same period a year ago.